Abstract: Recent progress in asymmetric syntheses has made a significant impact on strategies for drug development in the pharmaceutical industry. Under the recent guidelines by the Food and Drug Administration (FDA), many drug firms are no longer considering the development of racemic forms of chiral drugs. This lecture presents a few examples of highly practical stereoselective syntheses of drug candidates, shown below, discovered and developed at Merck Research Laboratories.
Introduction
Until recently, most drug firms have been developing racemic forms of chiral drugs. In contrast, Merck has been synthesizing a non-racemic isomer of a-methyldopa, AldometTM, on a multi-ton scale since the 1960's. The trend now is shifting as firms attempt to develop many of their chiral drugs as single enantiomers according to the recent guidelines published by the Food and Drug Administration (FDA). The extra steps and chemicals required for making single enantiomeric drugs in bulk quantity clearly result in much higher production costs. The establishment of practical stereoselective syntheses has therefore become an important goal for synthetic organic chemists, especially in the pharmaceutical industry.
Results and Discussion
As part of an ongoing program for the development of specific leukotriene antagonists for the treatment of asthma and other associated diseases, L-699,392 [3-[( 1 S)-[3(E) [2-(7-chloroquinolinyl)ethenyl]phenyl]-3-(ace~lphenyl)propylthio]-2(S)-methylpro-pionic acid was identified as a potent, orally active a ent. This new class of compounds is an has been replaced with a 2-arylethyl group. In order to carry out further studies, an efficient synthesis of this drug candidate was developed. The key diarylpropanone building block was prepared using the Heck coupling of the allylic alcohol. The ketone was then converted to the chiral hydroxy group by a Schlorodiisopinocampheylborane.
A novel rea ent prepared from lithiumhexamethyldisilazide and methylmagnesium chloride was utilize for the one step conversion of the ester to meth I ketone derivative. The introduction of the chiral mercapto side chain with inversion o the benzyl center was achieved via the mesylate activation of the chiral alcohol. 
L699,392
Two reagents for the chiral reduction of the ketone to the desired (R)-hydroxy ester were used: the oxazaborolidine-boranecomplex and Bchlorodiisopinocampheylborane. Althou h the former reagent provided exceptional enantioselectivity in the reduction (98.58 ee), the overreduction to the ethane-bridged by-product was a problem. The latter borane reducing reagent, although used stoichiometrically, can be prepared cheaply and easily from a-pinene and borane. The reagent showed no propensity for reduction of the C=C bond (< 1%) and gave only a slightly lower enantiomeric excess (98%). Brown, H. C., eta/ ., J. Org. Chem., 7987, 52, 5406. Merck process research, Syn. Commun., 1997 , 1705 Merck process research, J. Org. Chem., 1993, 58, 3731. commercially available chloroborane-methylsulfide complex or, alternatively, a 2:l mixture of borane and boron trichloride-methyl sulfide. Although dihaloboranes or alkylhaloboranes have been used before to prepare dialkylhaloboranes, this is the first application of this method to this reducing reagent. The reduction of the ketone with this reducing rea ent a-pinene. The isolated yield of hydroxy ester was 80% with > 99.5% ee. The nature of the selectivity of this reagent can be understood. The reactivity of racemic Bchlorodiisopinocamphe lborane derived from the racemic pinene was informative. B y hydroxy ester was observed. The racemic reducing reagent is composed of a statistical mixture of the (+,+),(-,-) and (+,-) species. The first two reagents are relatively active toward reduction, whereas, the last species, formally a mixture of two diastereomers, are relatively inactive or very slow reacting. According to this scenario and assuming a statistical mixture of the reagents was formed, the maximum asymmetric induction that one can obtain with 70% optically pure a-pinene is 94 Yo. The results match this predicted value closely.
gave the hydroxy ester in 97% ee. A tremendous asymmetric am lification resulting B rom 
MK-499
MK-499 is a potent potassium channel blocker that mediates repolarization of cardiac tissue and is under investigation for treatment of ventricular arrhythmias and the prevention of sudden cardiac death. A highly convergent route based on the asymmetric reduction of ketone intermediates was developed for its synthesis.
CN

MK4499 Br Br
HIV Protease Inhibitor, MK-0639
Numerous HIV protease inhibitors have been reported; however, very few of them have been studied in humans due to their poor oral bioavailability. A potent HIV protease inhibitor, MK-0639 demonstrates excellent oral bioavailability and plasma pharmacokinetic profiles in animals and in man. This compound inhibits the protease- 
L-738,372
Ongoing worldwide development of a new non-nucleosidal reverse transcriptase inhibitor, L-738,372 required a practical stereoselective synthesis in order to pursue animal safety studies and clinical trials. Stereocontrolled additions of carbon nucleophiles to aldehydes and aldimines have been developed with chiral auxiliaries on the electrophiles or nucleophiles and noncovalent bound chiral additives ' . Homogeneous THF solutions of acetylides and alkoxides were more selective than the suspensions obtained with toluene. The chiral additive method appears to be most advantageous since it avoids the auxiliary attachment and removal steps. For practical reasons, the search focused on readily available amino alcohols.
Ephedrine derivatives showed some selectivity, the most promising results were obtained with the cinchona alkaloids. Quinine and dihydroquinine both gave the required S-isomer while quinidine gave the other R-isomer with similar stereoselectivity. We chose quinine for further development due to its availability and cost. The protecting group on the distal nitrogen also played a key role in stereoselectivity of the addition. There is a substantial electronic influence as well as the effect of steric bulk at this remote position. The selectivity (98% ee) provided by the 9-anthrylmethyl group made it the protecting group of the choice for the synthesis of L-738,372. The scope of the reaction regarding imine variation remains to be explored.
L-743,726
We Since the enantiomeric excess of the product alcohol using lithiated cinchona alkaloids was only in the moderate range of 50 -60 Yo, we turned towards ephedrine alkaloids as another class of readily accessible amino alcohols. It was reported4 that the ephedrine nitrogen substituents can play an important role in the % ee of the product during the asymmetric alkylzinc addition to aldehydes in the presence of amino alcohols. The best ligand we found was 1 -phenyl-2-( 1 -pyrrolidinyl)propan-1-01. Upon optimizing the reaction conditions with this amino alcohol, we noticed that lithiations performed at 0 OC and cooled to -50 O C prior to adding the ketone gave desired addition product in high stereoselectivi (96-98 %ee). The optical purity of the product was enhanced to 99.5 enantioselective acetylide addition based on lithiated N-pyrrolidinyl norephedrine. We are currently studying the unusual temperature effect on the stereoselectivity of this reaction.
Yo ee by crysta ' y lization of the product in 80 % yield. Thus, we have developed a highly
